Ausgabe 3/2024
Inhalt (12 Artikel)
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors
- Open Access
- Research
Maxime Chénard-Poirier, Aaron R. Hansen, Martin E. Gutierrez, Drew Rasco, Yan Xing, Lin-Chi Chen, Heng Zhou, Andrea L. Webber, Tomoko Freshwater, Manish R. Sharma
Association between albumin–bilirubin grade and plasma trough concentrations of regorafenib and its metabolites M-2 and M-5 at steady-state in Japanese patients
- Open Access
- Research
Kazuma Fujita, Daiki Taguchi, Koji Fukuda, Taichi Yoshida, Kazuhiro Shimazu, Hanae Shinozaki, Hiroyuki Shibata, Masatomo Miura
KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non–small-cell lung cancer
- Open Access
- Research
Noboru Yamamoto, Miyako Satouchi, Toshihiko Doi, Yutaka Fujiwara, Noriko Yanagitani, Yoshitaka Kawa, Kiyotaka Yoh, Lance Leopold, Mihaela Munteanu, Takashi Sawada, Shirong Han, Kazuo Noguchi, Makoto Nishio
The suppression of cell motility through the reduction of FAK activity and expression of cell adhesion proteins by hAMSCs secretome in MDA-MB-231 breast cancer cells
- Research
Fatemeh Safari, Setareh Bararpour, Fatemeh Omidi Chomachaei
Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer
- Open Access
- Research
Tomoki Hori, Kazuhiro Yamamoto, Takefumi Ito, Shigeki Ikushima, Tomohiro Omura, Ikuko Yano
The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjects
- Research
Bei Cao, Tingting Ma, Yuqiang Zhang, Lei Huang, Hui Lin, Huanhuan Jiang, Yu Zhao, Yan Geng, Yuanxun Yang, Sumin Cao, Juan Li
Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia
- Open Access
- Research
Huifen Zhou, Xiaoxia Wu, Zhen Yang, Shenqi Lu, Xinhui Zhang, Xiaofei Yang, Suning Chen, Depei Wu, Miao Miao
The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer
- Open Access
- Research
Xinyi Liu, Zihan Guo, Lin Su, Anli Zuo, Min Gao, Xiang Ji, Jiameng Lu, Shuran Yang, Yunxiu Jiang, Degan Lu
In vitro results with minimal blood toxicity of a combretastatin A4 analogue
- Research
Camila Chagas, Jaqueline Vital Mansano, Emerson Barbosa da Silva, Giuliana Petri, Beatriz da Costa Aguiar Alves Reis, Maria Lúcia Schumacher, Paula Silvia Haddad, Edimar Cristiano Pereira, Tatiane Nassar Britos, Eliezer J. Barreiro, Lídia Moreira Lima, Fabio Furlan Ferreira, Fernando Luiz Affonso Fonseca
Evolving or immutable - phase I solid tumor trials in the era of precision oncology
- Open Access
- Research
Shannon S. Stockton, G. Dan Ayers, Cody Lee, Heather Laferriere, Satya Das, Jordan Berlin
Toxicity burden patterns of MET-selective tyrosine kinase inhibitors: evidence from real-world pharmacovigilance
- Brief Report
Wenjie Li, Wei Wang
Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial
- Open Access
- Correction
Andrew J. Armstrong, Ravit Geva, Hyun Cheol Chung, Charlotte Lemech, Wilson H. Miller Jr, Aaron R. Hansen, Jong-Seok Lee, Frank Tsai, Benjamin J. Solomon, Tae Min Kim, Christian Rolfo, Vincent Giranda, Yixin Ren, Fang Liu, Bhargava Kandala, Tomoko Freshwater, Judy S. Wang
